Thank you, Chair.
Thank you, folks, for coming today. We're sorry for the delay because of the votes in the House, but here we go.
My first question is to you, Carla. It's about the cutbacks. You mentioned cutbacks, I think by Health Canada, slowing down product introduction.
But you also stated that there were cutbacks or that there was no approval of funding under Growing Forward 2—was it?—for research. Can you give me a quick snapshot of what is happening? If research has been cut back and approval mechanisms are cut, how is that going to impact your products, especially if we're going to be looking at introducing products into European markets?